Background Measuring a country's health performance has focused mostly on estimating levels of mortality. An alternative is to measure rates of decline in mortality, which are more sensitive to changes in health policy than are mortality levels. Historical rates of decline in mortality can also help test the feasibility of future health goals (eg, post-2015). We aimed to assess the annual rates of decline in under-5, maternal, tuberculosis, and HIV mortality over the past two decades for 109 low-income and middle-income countries.
Introduction
Assessing a country's health performance is diffi cult. Across and within countries, policies can aff ect population health directly or indirectly and might vary substantially in scope and delivery. This diversity and complexity challenges our understanding of the systemic causes of success or failure and, ultimately, limits crosscountry comparability. 1 A country's performance in health is typically defi ned by how much better or worse it is faring with respect to a selected outcome (eg, life expectancy) compared with what would be expected in view of selected contextual attributes (eg, income and education). 2 In the Good
Health at Low Cost study, 3 an attempt was made to assess country performances in levels of mortality; a case-study approach was used to examine why three countries and one Indian state had low mortality levels despite scant resources. Later analyses also quantifi ed performance with respect to levels of mortality and fertility. 4 Numbers of deaths are aff ected strongly by longstanding country-level determinants. Essentially, a country that starts with a low level of mortality is likely to persist with fewer deaths, whereas a country that begins at a high level might improve substantially but still have comparatively higher mortality. Thinking about alterations in the number of deaths or annual rates of change in mortality is useful for understanding how a country's health performance might relate to adjustments in policy. Most published work on country performance focuses on estimates for mortality levels, but some studies are beginning to emerge in which rates of change are investigated. [5] [6] [7] [8] [9] [10] [11] [12] [13] To the extent that rates of change are responsive to the introduction of health policies (eg, a new immunisation programme), rates of decline in mortality off er a dependent variable to understand the eff ect on performance of social and system determinants. Nevertheless, rates of change-like any one-dimensional metric-still present weaknesses. Notably, large declines from high levels of mortality will still lead to an unacceptably large number of deaths. Therefore, rates of change complement rather than replace the important information conveyed by estimates of mortality levels.
The need to measure progress in health has been especially apparent in relation to assessing whether countries are on track to achieve the Millennium Development Goals. [10] [11] [12] [13] Measuring progress will also be crucial to ascertain whether countries can achieve the next set of post-2015 Sustainable Development Goals, which are ready to be adopted by UN member states in 2015. The Sustainable Development Goals are likely to include one health goal with an associated set of targets; several proposals are under discussion.
14 The Lancet's Commission on Investing in Health proposed the target of achieving a "grand convergence in global health" by 2035, defi ned as cutting infectious, maternal, and child deaths to universally low levels (eg, those seen today in the best-performing middle-income countries such as Chile and Turkey). 15 Other targets have been proposed by the Global Investment Framework for Women's and Children's Health, 16 UNICEF, 17 the Sustainable Development Solutions Network, 18 and the High-Level Panel on the post-2015 development agenda 19 (table 1) . An intergovernmental open working group recently published a draft of the Sustainable Development Goals. 20 Over the next year, these will be debated by all UN member states and might undergo revision, before adoption in September, 2015.
Studying historical rates of change (rates of decline) in mortality across countries over recent decades can be helpful to test the feasibility of these diff erent proposals, many of which include very ambitious targets for child, maternal, tuberculosis, and HIV mortality that would require high rates of decline from 2015 to 2030 (the probable end date for the Sustainable Development Goals). Such targets for mortality can be reality-tested by looking at whether high rates of decline in mortality have ever been achieved by any low-income or middle-income country and could be reproduced for the period 2015-30, to enable such ambitious mortality goals to be achieved.
Assessment of a country's health performance with respect to changes in rates of decline in mortality is, therefore, valuable when studying the eff ects of policy and for testing the feasibility of proposed post-2015 health goals. We aimed to examine the change in the annual rate of decline of key mortality indicators for 109 low-income and middle-income countries over the period 1990-2013.
Methods
For our analysis, we selected four indicators that were almost always listed among proposals for post-2015 health targets ( mortality (incidentally, these indicators are encompassed largely within under-5 mortality) or infectious disease mortality more generally. In some regions (eg, southern Africa), HIV and tuberculosis mortality correlate highly, whereas in others (eg, north Africa and the Middle East), these infectious diseases are not major causes of death.
We assessed the rates of decline in the four chosen mortality indicators for 109 low-income and middleincome countries (as defi ned by the World Bank) 21 with populations greater than 1 million people. 22 The appendix (p 1) lists the countries included in the analysis.
We estimated rates of decline in under-5 mortality (ie, the number of children who die after birth before age 5 years) per 1000 livebirths, the maternal mortality ratio (ie, the number of pregnant women who die) per 100 000 livebirths, tuberculosis mortality (ie, the number of deaths from tuberculosis) per 100 000 population per year, and HIV mortality (ie, the number of HIV-related deaths) per 100 000 population per year. Owing to availability of data, we used a 1992-2012 time series for under-5 mortality 23 and tuberculosis mortality, 24 a 1990-2013 time series for the maternal mortality ratio, 25 and a 2000-10 time series for HIV mortality. 26 We [23] [24] [25] [26] and for consistency, with the exception of the last increment for maternal mortality, which is over an 8-year period.
We calculated the annual rate of change in the annual rate of decline (either an acceleration or deceleration) for every transition from one 5-year interval to the next, from 1990 to 2013 (fi gure 1B). In total, we have three values for the rate of change in the rate of decline for every country for under-5 mortality and tuberculosis mortality (1992- . Note that we use the rates of decline from two consecutive 5-year intervals (eg, 1995-2000 and 2000-05) to estimate a rate of change in the rate of decline for the transition between those two intervals. When estimates are available, we could analyse continuously a country's rate of decline per year and annual rate of change in the rate of decline. Such an analysis could point to rapid changes over short periods, and whether acceleration or deceleration takes place that is worthy of subsequent assessment. However, annual estimates are only available for under-5 mortality (appendix p 2). Therefore, for the sake of reporting consistency, we present fi ndings in 5-year intervals, which also enables clear and concise interpretation of results.
For every mortality indicator, we estimated the year by which The Lancet's Commission on Investing in Health target 15 would be achieved (fi gure 1C). We obtained estimates for every country's latest rates of decline, aspirational best-performer rates of decline (ie, the 90th percentile for all countries of rates of decline), and aspirational rates of decline at the regional level (ie, 90th percentile for regional rates of decline). The list of regions is presented in the appendix (p 1).
Role of the funding source
The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all data in the paper and SV and DTJ had fi nal responsibility for the decision to submit for publication. Tables 2 to 5 show the rates of decline in mortality indicators and highlight the best and worst country performers (top-fi ve and bottom-fi ve rates of decline). For under-5 mortality and maternal mortality, the distribution of rates of decline among the 109 low-income and middleincome countries is narrow (appendix p 3) and becomes narrower in the most recent period (2007-12 and 2005-13, Figure 1 : Calculations (A) L(t) represents the level of a selected indicator-eg under-5 mortality ratein a given country at time t. We calculated the annual rate of change of L(t), denoted R(t). The denominator 5 corresponds to the 5-year interval in the numerator. Although we generally used 5-year time intervals, occasionally it was appropriate to use a diff erent interval; we have noted these cases in the report and made the appropriate adjustments. (B) Periods of rapid improvements (or worsening) of R(t) are also of policy interest. We calculated RCR(t), the rate of change in R(t). (C) Given a rate of change, R, in an indicator from its initial level, L, we also calculated the number of years, y, it would take to reach a target T-eg, a target under-5 mortality rate of 20 per 1000 livebirths. Worst performers 
Results
[L(t+5)-L(t)] 5L(t) R(t) = [R(t+5)-R(t)] 5R(t) RCR(t) = [In(T)-In(L)] y = R See1 Malaysia -1·0% (-1·3 to -0·6) Lesotho -0·2% (-0·6 to 0·2) Swaziland -4·2% (-4·7 to -3·7) Botswana -7·3% (-7·9 to -6·7) 2 Costa Rica 1·0% (0·6 to 1·3) Mauritius -0·1% (-0·5 to 0·3) South Africa -4·1% (-4·6 to -3·6) Swaziland -7·0% (-7·6 to -6·4) 3 Vietnam 1·3% (0·9 to 1·6) Somalia 0·3% (-0·1 to 0·7) Botswana -3·4% (-3·9 to -2·9) Rwanda -5·6% (-6·2 to -5·0) 4 Zimbabwe 1·3% (1·0 to 1·7) DRC 0·4% (0·0 to 0·8) Lesotho -3·3% (-3·8 to -2·8) Zimbabwe -4·3% (-4·9 to -3·7) 5 Mauritius 1·4% (1·1 to 1·8) Zimbabwe 0·8% (0·4 to 1·2) Namibia -1·1% (-1·6 to -0·6) Lesotho -3·6% (-4·2 to -3·0) UI=uncertainty interval.
Worst performers
UI=uncertainty interval. Contrary to under-5 mortality and the maternal mortality ratio, for tuberculosis mortality, the distribution of rates of decline is wider and shows little change over time (appendix p 3 
UI=uncertainty interval. For HIV mortality, 47 (43%) of 109 countries have already achieved The Lancet's Commission on Investing in Health target of eight deaths per 100 000 population per year and 62 have not. At current rates, 28 (45%, 95% UI 26-50) of these 62 countries would achieve the target by 2030 and 11 (18%, 18-29) would achieve it over the period 2030-50 (fi gure 3J). At the aspirational rate, 49 (79%, 66-82) would achieve the target by 2030 and the remaining 13 (21%, 18-34) would achieve it over the period 2030-40 (fi gure 3K). At regional aspirational rates, 42 (68%, 52-82) would achieve the target by 2030 and 16 (26%, 18-32) countries would achieve it over the period 2030-40 (fi gure 3L).
Discussion
We studied over the past two decades the historical rates of decline of under-5, maternal, tuberculosis, and HIV mortality for 109 countries of low and middle income. Between 2005 and 2013, the mean rates of decline were 4·3% (95% UI 3·9-4·6) per year for under-5 mortality, 3·3% (2·5-4·1) per year for maternal mortality, 4·1% (2·8-5·4) per year for tuberculosis mortality, and 2·2% (0·1-4·3) per year for HIV mortality. Best-performer rates of decline per year were 7·1% (6·8-7·5), 6·3% (5·5-7·1), 12·8% (11·5-14·1), and 15·3% (13·2-17·4), respectively, with substantial variation across countries and regions. During the period 1990-2013, we also identifi ed countries with the best and worst performances and regions in which rapid changes had taken place towards higher or lower performance. Our two aims in looking at trends in the rates of decline were to provide a dependent variable to assist in identifying potential health policy determinants of performance and to fi nd an approach to testing the feasibility of proposed post-2015 health goals. We aimed to identify specifi c countries and periods with good and bad performances in rates of decline of mortality indicators, for which further assessment would be valuable. Analysing all potential determinants of the rates of decline-including contextual factors, specifi c circumstances, and system and policy elements-could provide useful lessons for improvement of population health in the future. Importantly, a country's health performance could be classifi ed by how much the rate of decline of a selected outcome (eg, under-5 mortality) is better or worse than what would be expected with selected contextual attributes (eg, income, education). In a subsequent analysis, specifi c variables could be analysed (eg, health expenditure, foreign aid) that might isolate the remaining determinants of country performance.
Analysis of rates of change in health is useful because rapid alterations in rates of decline-whether accelerations or decelerations-can point to a potential eff ect of policy changes and provide a mechanism to better understand what constitutes good policy. We noted almost no correlation between numbers of deaths and rates of decline in mortality indicators (fi gure 2), which suggests that rates of change augment the information conveyed by mortality estimates but cannot replace the important part played by examination of numbers of deaths, particularly in terms of capturing the underlying intensity of country-level mortality.
Rates of decline in child mortality indicate the severe eff ect that the HIV/AIDS epidemic had in southern Africa. In this region, very large increases were recorded in child mortality over the period 1997-2002, but numbers of deaths fell rapidly from 2002 to 2007, probably because of rollout of antiretroviral therapy (ART) for the prevention of mother-to-child transmission of HIV. 27, 28 Likewise, rates of decline in maternal and tuberculosis mortality deteriorated during 1990-97 in many central Asian countries after the collapse of the Soviet Union in 1991, and rates of decline in child mortality dropped abruptly in Rwanda from 1992 to 1997, probably because of the genocide in 1994. A few countries have sustained high rates of decline-eg, child mortality in Turkey from 1992 to 2007, maternal mortality in Cambodia over the period 1990-2005, tuberculosis mortality in Rwanda between 1997 and 2007, and HIV mortality in Burkina Faso during 2000-10. Did unusual circumstances or specifi c policies account for these changes in mortality? Indeed, subsequent assessments could control for contextual determinants (eg, income) and exceptional events (eg, natural disasters and political instabilities) and try to identify the contributions of specifi c policies implemented. For instance, Turkey's high rates of decline in child mortality coincide with substantial economic growth, political stability, and introduction of the Health Transformation Program, which rapidly expanded access to health-care services. 29 Cambodia's progress in maternal mortality can probably be attributed to socioeconomic improvements and better primary education and to specifi c policies leading to increases in skilled birth attendance. 30 For Burkina Faso, We used the rates of decline in mortality to test the feasibility of achieving post-2015 goals, with a particular focus on the 2030 targets proposed by The Lancet's Commission on Investing in Health. Because post-2015 goals present ambitious targets for levels of mortality, they would need high (aspirational) rates of mortality decline from 2015 to 2030. Hence, we used historical rates of decline-including best-performer aspirational rates-to identify how many countries would achieve these ambitious targets if they were to have these similar rates of decline over the period 2015-30. If all countries of low and middle income were able to achieve best-performer aspirational rates of decline in mortality, most would meet the targets for tuberculosis and HIV mortality, about half would reach the child mortality target, but fewer than half would meet the maternal mortality target.
Similar methods can be used to assess the feasibility of other possible Sustainable Development Goal targets. Norheim and colleagues 32 suggested (in addition to specifi c subtargets for under-5 mortality, etc) an overarching goal to reduce premature (younger than 70 years) deaths by 40% in 2030 from what they would have been in 2010. Figure 4 shows mortality estimates for 2030 that were predicted from the distribution of changes in rates of decline in premature deaths across countries in 2000-10. To the right of the cutoff , 21 countries had rates of decline suffi ciently rapid that, if continued for two decades to 2030, they would meet the 40% reduction target.
Periods of high rates of decline in mortality, such as those seen among best-performers (tables 2 to 5), can be diffi cult to sustain. Indeed, we noted a strong negative correlation between the rate of decline and the rate of change in the rate of decline (eg, -0·60 and -0·80 for under-5 mortality and the maternal mortality ratio, respectively). Thus, when high rates of decline were recorded, negative rates of change in rates of decline (ie, decelerations) were sometimes recorded, leading to a reduction from higher to lower rates of decline.
Even if some countries can emulate the best performances recorded in recent years with respect to rates of decline in infectious, child, and maternal mortality, our fi ndings suggest they will not meet proposed 2030 global health targets. These countries will need to achieve highly accelerated rates of decline in mortality. How can such acceleration be achieved? A fi rst approach would be aggressive and accelerated scale-up of evidence-based medicines, vaccines, diagnostics, and other health strategies to very high coverage levels; a second would be to scale-up investments in discovery, development, and delivery of new health technologies. Both these approaches were captured in The Lancet's Commission on Investing in Health modelling method but were not included in our best-performer modelling. Two methodological diff e rences could account for why some countries in our model did not reach 2030 targets. First, the Commission's approach began by modelling the scale-up of a wide range of evidence-based interventions (eg, ART and skilled birth attendance) to very high (typically 90%) coverage levels by 2030. The model assumes that very aggressive intervention scale-up will be possible across all countries of low and middle income based on actual rates of scale-up in recent years in several countries. Second, the Commission's model also assumes that discovery and development of new medicines, vaccines, and diagnostics will lead to an additional 2% per year decline in under-5, maternal, HIV, and tuberculosis mortality, an assumption based on empirical research on the eff ect of research and development on mortality declines. 33 Taken together, these diff erences indicate that the Commission's modelling is more optimistic than is ours about what can be achieved by 2030.
Our analysis has four key limitations. First, for some countries with poor data, the mortality estimates we used [23] [24] [25] [26] were predicted largely from past trends. Many countries, particularly those with high mortality, do not have vital registration so mortality estimates are not always reliable. In view of the large number of countries and distinct mortality indicators analysed, some fi ndings might also be attributable to poor quality of data. We used UNICEF and WHO mortality estimates [23] [24] [25] [26] to draw general lessons, but our fi ndings could be further strengthened by incorporation of additional sources (panel). 12, 13, [34] [35] [36] Second, 5-year intervals were chosen because of the availability of estimates [23] [24] [25] [26] and for conciseness, but this Density of countries period might oversmooth changes of interest. If available, alternative intervals could be analysed, which would aff ect country performance rankings. Despite noise, annual outcomes could be looked at to isolate infl ection points that capture times when countries make performance transitions (appendix p 2). This approach would also help identify seasonal variations and cyclical patterns that longer intervals (eg, every 5 years) might be unable to fl ag. The choice of interval represents a trade-off between accuracy and the relevance of fi ndings to policy. A third limitation is that our analysis includes four mortality indicators that correlate highly across countries for a specifi c period and over time for a particular country. For example, correlation over the entire period was 0·90 between the maternal mortality ratio and under-5 mortality, 0·58 for under-5 and tuberculosis mortality, and 0·59 for the maternal mortality ratio and tuberculosis mortality. Correlation might aff ect the feasibility of the post-2015 targets, because countries achieving poor results for one indicator might be faring badly in another. Nevertheless, we noted little correlation between the rates of decline of the four indicators: 0·35 between under-5 mortality and the maternal mortality ratio, 0·15 for under-5 and tuberculosis mortality, and -0·01 for the maternal mortality ratio and tuberculosis mortality, which suggests that successful improvements towards targets might not be aff ected.
The fi nal limitation is that other modelling techniques could be used to forecast the rates of decline in mortality and to ascertain whether countries would achieve targets by 2030. For instance, specifi c explanatory variables related to declines in mortality could be used, and regression models could be fi tted to mortality time series to make future predictions. However, we opted for a simple and intuitive approach based on historical rates of decline in mortality, which are easily communicable to policymakers.
In conclusion, if recent aspirational best-performer rates of decline could be achieved in countries of low and middle income, most would meet The Lancet's Commission on Investing in Health targets for 2030 for tuberculosis and HIV mortality, about half would reach the child mortality target, and fewer than half would meet the maternal mortality target. Aggressive scale-up of evidence-based interventions together with discovery and development of new health strategies will be needed to achieve further acceleration of declines in mortality. Rates of decline provide a necessary starting point for assessment of the importance of health policy determinants and for defi ning realistic targets for the Sustainable Development Goals.
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Panel: Research in context
Systematic review Suggested post-2015 targets (eg, the Sustainable Development Goals) have only recently been published, 14, 20 and a preliminary search by us did not identify any study addressing exactly our aim to estimate the annual rates of decline in under-5, maternal, tuberculosis, and HIV mortality over the past two decades. Therefore, we did not do a systematic review. Published work has begun to emerge in which the rates of change (rates of decline) in mortality indicators are used to identify rapid alterations in numbers of deaths in selected countries and over periods that are worthy of further exploration. [5] [6] [7] [8] [9] [11] [12] [13] [34] [35] [36] The motivation for studying rates of change is that these data are expected to be sensitive to changes in intersectoral, social, and health system policies. In particular, assessment of country performances with respect to rates of decline in mortality indicators enables reporting on progress towards achieving goals such as the "grand convergence in global health" objective highlighted by The Lancet's Commission on Investing in Health and extrapolating on what could be post-2015 targets (eg, the Sustainable Development Goals). Here, we report trends in rates of decline of under-5, maternal, tuberculosis, and HIV mortality for 109 low-income and middle-income countries over the period 1990-2013.
Interpretation
Country performance with respect to rates of decline in mortality indicators provides a quantitative starting point for assessment of the importance of intersectoral, social, and system determinants of health and for realistic achievement of future set objectives, such as the Sustainable Developmen t Goals.
